Want to track PRM and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
PRM closed yesterday lower at 1.66 GBX, a decrease of -7.7389% from Friday's close, completing a monthly increase of 0.6485% or 0.01 GBX. Over the past 12 months, PRM stock lost -10.7151%.
PRM is not paying dividends to its shareholders.
The stock of the company had never split.
The company's stock is traded on 6 different exchanges and in various currencies, with the primary listing on LSE (GBX).
Proteome Sciences plc (PRM) FAQ
What is the stock price today?
The current price is 1.66 GBX.
On which exchange is it traded?
Proteome Sciences plc is listed on LSE.
What is its stock symbol?
The ticker symbol is PRM.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 8.59M.
Has Proteome Sciences plc ever had a stock split?
No, there has never been a stock split.
Proteome Sciences plc Profile
| Professional Services Industry | Industrials Sector | Christopher Donovan James Pearce CEO | LSE Exchange | - ISIN |
| GB Country | 36 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Proteome Sciences plc is a renowned company specializing in contract research services with a focus on the identification, validation, and application of protein biomarkers. It operates across various geographical locations, including the United States, the United Kingdom, the European Union, and other international regions. Established in 1993 and headquartered in Cobham, the United Kingdom, Proteome Sciences plc caters primarily to pharmaceutical and biotechnology companies, along with academic research institutes. The company is dedicated to advancing the field of proteomics through its innovative approaches in analyzing protein activities and biomarker discovery.
Products and Services
- SysQuant - Provides a comprehensive analysis of protein activity across regulatory and signaling pathways, aiding in the in-depth investigation of cellular processes and disease mechanisms.
- TMT MS2 - A specialized technique for analyzing cells and tissues when phosphopeptide enrichment is not required. It allows for the detailed study of protein expression and modification in various biological samples.
- TMT MS3 - Represents an advanced method for biomarker discovery in plasma and other complex samples. TMT MS3 is tailored for projects where quantitative accuracy is paramount, ensuring precise measurement of protein levels.
- TMT Calibrator - Facilitates the analysis of diseased or treated tissue in parallel with peripheral fluids. This approach enhances the understanding of disease pathology and the effects of therapeutic interventions.
- TMT SRM - A targeted assay format designed for the rapid validation of biomarker candidates. TMT SRM combines the precision of targeted mass spectrometry with the efficiency of the TMT labeling approach.
- SRM Assay - A targeted mass spectrometry assay format dedicated to the routine measurement of biomarkers. It offers high specificity and sensitivity for the quantitative analysis of proteins in complex biological matrices.
- Bioinformatics Tools - Proteome Sciences plc provides a suite of bioinformatics tools that support the analysis and interpretation of proteomics data. These tools facilitate the understanding of complex datasets, enhancing biomarker discovery and validation efforts.
Contact Information
Address: Coveham House
Phone: 44 20 7043 2116
Website: https://www.proteomics.com
